EDITAS MEDICINE INC.

Editas Medicine Presents Preclinical Data on Novel Engineered iPSC-derived NK Cells for the Treatment of Cancer at the Society for Immunotherapy of Cancer 36th Annual Meeting

12 Nov 2021 07:00:02 By Nasdaq GlobeNewswire

Editas Medicine Announces Third Quarter 2021 Results and Business Updates

08 Nov 2021 07:00:01 By Nasdaq GlobeNewswire

Editas Medicine to Present Data Demonstrating Progress Towards Transformative Gene Editing Medicines for the Treatment of Hemoglobinopathies and Cancer at the ASH Annual Meeting and Exposition

04 Nov 2021 09:02:00 By Nasdaq GlobeNewswire

Editas Medicine Names Bernadette Connaughton to Board of Directors

28 Oct 2021 09:00:02 By Nasdaq GlobeNewswire

Editas Medicine to Host Conference Call Discussing Third Quarter 2021 Results and Corporate Update

25 Oct 2021 16:01:00 By Nasdaq GlobeNewswire

Clinical Data from Editas Medicine’s Ongoing Phase 1/2 BRILLIANCE Clinical Trial of EDIT-101 for LCA10 to be Presented at the European Society of Gene and Cell Therapy Annual Congress

20 Oct 2021 09:00:01 By Nasdaq GlobeNewswire

Editas Medicine to Present Preclinical Data on Novel Engineered iPSC Derived NK Cells for the Treatment of Cancer at the Society for Immunotherapy of Cancer 36th Annual Meeting

07 Oct 2021 08:00:01 By Nasdaq GlobeNewswire

Editas Medicine to Present at Chardan’s 5th Annual Genetic Medicines Conference

30 Sep 2021 08:00:00 By Nasdaq GlobeNewswire

Editas Medicine Announces Positive Initial Clinical Data from Ongoing Phase 1/2 BRILLIANCE Clinical Trial of EDIT-101 for LCA10

29 Sep 2021 09:00:01 By Nasdaq GlobeNewswire

Editas Medicine Names Emma Reeve to Board of Directors

08 Sep 2021 09:00:01 By Nasdaq GlobeNewswire